Pfizer, J&J shifts spare HCP shops

Share this article:
Pfizer
Pfizer

For the big mainline ad agencies, the recent creative consolidations at Pfizer and Johnson & Johnson are a big deal. To their medical agency subsidiaries, however, the changes mostly represent a codification of where things stood to begin with.

In October, Pfizer narrowed the provision of its global creative to three holding companies—Omnicom, WPP and Publicis—that held the lion's share of the business already. The bulk of the drug maker's creative accounts are handled by Omnicom shops, particularly CDM New York, though a couple of Interpublic agencies could lose out (Draftfcb for Spriva HandiHaler, which Pfizer co-promotes with Boehringer Ingelheim, and McCann Humancare for Toviaz and Premarin VC), as do a few indie shops (Concentric for European work on Lipitor and Caduet, as well as Enbrel US).

Pfizer said that the transition is expected to take place “over the course of 2013 and 2014,” so those shops that got the worst of the deal will have some time to replace the lost business. The review of global marketing support included all businesses with the exception of the company's Nutrition and Animal Health units. An “e-auction” which featured blinded online bidding was, as reported in Advertising Age, used “for a portion of the assessment,” Pfizer confirmed, but “wasn't a major determinant.”

J&J's review, which concluded earlier in the month, resulted in the consumer marketing giant consolidating advertising creative on OTC and packaged goods brands into WPP and Omnicom. Interpublic's Lowe lost some business on Tylenol and feminine-hygiene brands, but the review didn't cover the company's prescription drugs and devices, where Interpublic's Draftfcb, ICC Lowe and McCann Health networks have a strong presence.

However, Interpublic isn't in the clear just yet – the conglomerate's Universal McCann boasts a big chunk of J&J's media buying and planning business, which the company threw into review as soon as the creative consolidation was completed.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets

Private View: New ways to engage with customers

Private View: New ways to engage with customers

These healthcare social media campaigns successfully use emotion, altruism and the human desire to "brand" oneself to get customers engaged.